MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
Cancer Research UK Edinburgh Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
Br J Cancer. 2020 Nov;123(11):1705-1712. doi: 10.1038/s41416-020-01060-8. Epub 2020 Sep 15.
Low circulating vitamin D levels are associated with poor colorectal cancer (CRC) survival. We assess whether vitamin D supplementation improves CRC survival outcomes.
PubMed and Web of Science were searched. Randomised controlled trial (RCTs) of vitamin D supplementation reporting CRC mortality were included. RCTs with high risk of bias were excluded from analysis. Random-effects meta-analysis models calculated estimates of survival benefit with supplementation. The review is registered on PROSPERO, registration number: CRD42020173397.
Seven RCTs (n = 957 CRC cases) were identified: three trials included patients with CRC at outset, and four population trials reported survival in incident cases. Two RCTs were excluded from meta-analysis (high risk of bias; no hazard ratio (HR)). While trials varied in inclusion criteria, intervention dose and outcomes, meta-analysis found a 30% reduction in adverse CRC outcomes with supplementation (n = 815, HR = 0.70; 95% confidence interval (CI): 0.48-0.93). A beneficial effect was seen in trials of CRC patients (progression-free survival, HR = 0.65; 95% CI: 0.36-0.94), with suggestive effect in incident CRC cases from population trials (CRC-specific survival, HR = 0.76; 95% CI: 0.39-1.13). No heterogeneity or publication bias was noted.
Meta-analysis demonstrates a clinically meaningful benefit of vitamin D supplementation on CRC survival outcomes. Further well-designed, adequately powered RCTs are needed to fully evaluate benefit of supplementation in augmenting 'real-life' follow-up and adjuvant chemotherapy regimens, as well as determining optimal dosing.
低循环维生素 D 水平与结直肠癌(CRC)不良预后相关。我们评估了维生素 D 补充是否能改善 CRC 生存结局。
检索了 PubMed 和 Web of Science。纳入了报告 CRC 死亡率的维生素 D 补充随机对照试验(RCT)。高偏倚风险的 RCT 被排除在分析之外。采用随机效应荟萃分析模型计算补充维生素的生存获益估计值。该综述已在 PROSPERO 上注册,注册号:CRD42020173397。
共确定了 7 项 RCT(n=957 例 CRC 病例):其中 3 项试验纳入了初诊 CRC 患者,4 项人群试验报告了新发 CRC 病例的生存情况。2 项 RCT 因高偏倚风险(无风险比(HR))而被排除在荟萃分析之外。虽然这些试验在纳入标准、干预剂量和结局方面存在差异,但荟萃分析发现,补充维生素可使 CRC 不良结局减少 30%(n=815,HR=0.70;95%置信区间(CI):0.48-0.93)。在 CRC 患者的试验中观察到有益效果(无进展生存期,HR=0.65;95%CI:0.36-0.94),人群试验中对新发 CRC 病例也有提示性效果(CRC 特异性生存,HR=0.76;95%CI:0.39-1.13)。未发现异质性或发表偏倚。
荟萃分析表明,维生素 D 补充对 CRC 生存结局有显著的临床获益。需要进一步设计良好、充分有力的 RCT 来全面评估补充维生素在增强“真实世界”随访和辅助化疗方案以及确定最佳剂量方面的获益。